Moderna Competitors

Moderna (NASDAQ:MRNA) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, dividends and profitability.

Analyst Ratings

This is a breakdown of recent recommendations for Moderna and Amgen, as reported by MarketBeat.

Moderna presently has a consensus price target of $149.6471, suggesting a potential upside of 7.35%. Amgen has a consensus price target of $259.4091, suggesting a potential upside of 4.21%. Given Moderna's higher possible upside, equities analysts plainly believe Moderna is more favorable than Amgen.

Risk & Volatility

Moderna has a beta of 1.73, indicating that its share price is 73% more volatile than the S&P 500. Comparatively, Amgen has a beta of 0.76, indicating that its share price is 24% less volatile than the S&P 500.

Profitability

This table compares Moderna and Amgen's net margins, return on equity and return on assets.

Institutional and Insider Ownership

51.2% of Moderna shares are held by institutional investors. Comparatively, 75.2% of Amgen shares are held by institutional investors. 29.2% of Moderna shares are held by insiders. Comparatively, 0.4% of Amgen shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Moderna and Amgen's top-line revenue, earnings per share and valuation.

Amgen has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Summary

Amgen beats Moderna on 10 of the 14 factors compared between the two stocks.

Moderna (NASDAQ:MRNA) and Gilead Sciences (NASDAQ:GILD) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, dividends and profitability.

Analyst Ratings

This is a breakdown of recent recommendations for Moderna and Gilead Sciences, as reported by MarketBeat.

Moderna presently has a consensus price target of $149.6471, suggesting a potential upside of 7.35%. Gilead Sciences has a consensus price target of $97.2308, suggesting a potential upside of 50.37%. Given Gilead Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Gilead Sciences is more favorable than Moderna.

Risk & Volatility

Moderna has a beta of 1.73, indicating that its share price is 73% more volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500.

Profitability

This table compares Moderna and Gilead Sciences' net margins, return on equity and return on assets.

Institutional and Insider Ownership

51.2% of Moderna shares are held by institutional investors. Comparatively, 76.4% of Gilead Sciences shares are held by institutional investors. 29.2% of Moderna shares are held by insiders. Comparatively, 0.1% of Gilead Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Moderna and Gilead Sciences' top-line revenue, earnings per share and valuation.

Gilead Sciences has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Summary

Gilead Sciences beats Moderna on 11 of the 14 factors compared between the two stocks.

Moderna (NASDAQ:MRNA) and Biogen (NASDAQ:BIIB) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, dividends and profitability.

Analyst Ratings

This is a breakdown of recent recommendations for Moderna and Biogen, as reported by MarketBeat.

Moderna presently has a consensus price target of $149.6471, suggesting a potential upside of 7.35%. Biogen has a consensus price target of $303.5862, suggesting a potential upside of 15.52%. Given Biogen's higher possible upside, analysts plainly believe Biogen is more favorable than Moderna.

Risk & Volatility

Moderna has a beta of 1.73, indicating that its share price is 73% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.53, indicating that its share price is 47% less volatile than the S&P 500.

Profitability

This table compares Moderna and Biogen's net margins, return on equity and return on assets.

Institutional and Insider Ownership

51.2% of Moderna shares are held by institutional investors. Comparatively, 83.5% of Biogen shares are held by institutional investors. 29.2% of Moderna shares are held by insiders. Comparatively, 0.5% of Biogen shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Moderna and Biogen's top-line revenue, earnings per share and valuation.

Biogen has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Summary

Biogen beats Moderna on 10 of the 14 factors compared between the two stocks.

Moderna (NASDAQ:MRNA) and BioNTech (NASDAQ:BNTX) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, dividends and profitability.

Analyst Ratings

This is a breakdown of recent recommendations for Moderna and BioNTech, as reported by MarketBeat.

Moderna presently has a consensus price target of $149.6471, suggesting a potential upside of 7.35%. BioNTech has a consensus price target of $105.50, suggesting a potential downside of 13.18%. Given Moderna's higher possible upside, equities analysts plainly believe Moderna is more favorable than BioNTech.

Risk & Volatility

Moderna has a beta of 1.73, indicating that its share price is 73% more volatile than the S&P 500. Comparatively, BioNTech has a beta of -1.74, indicating that its share price is 274% less volatile than the S&P 500.

Profitability

This table compares Moderna and BioNTech's net margins, return on equity and return on assets.

Institutional and Insider Ownership

51.2% of Moderna shares are held by institutional investors. Comparatively, 10.8% of BioNTech shares are held by institutional investors. 29.2% of Moderna shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Moderna and BioNTech's top-line revenue, earnings per share and valuation.

BioNTech has higher revenue and earnings than Moderna. BioNTech is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Summary

Moderna beats BioNTech on 9 of the 14 factors compared between the two stocks.

Moderna (NASDAQ:MRNA) and Seagen (NASDAQ:SGEN) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, dividends and profitability.

Analyst Ratings

This is a breakdown of recent recommendations for Moderna and Seagen, as reported by MarketBeat.

Moderna presently has a consensus price target of $149.6471, suggesting a potential upside of 7.35%. Seagen has a consensus price target of $185.3571, suggesting a potential upside of 31.72%. Given Seagen's stronger consensus rating and higher possible upside, analysts plainly believe Seagen is more favorable than Moderna.

Risk & Volatility

Moderna has a beta of 1.73, indicating that its share price is 73% more volatile than the S&P 500. Comparatively, Seagen has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500.

Profitability

This table compares Moderna and Seagen's net margins, return on equity and return on assets.

Institutional and Insider Ownership

51.2% of Moderna shares are held by institutional investors. Comparatively, 87.2% of Seagen shares are held by institutional investors. 29.2% of Moderna shares are held by insiders. Comparatively, 31.1% of Seagen shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Moderna and Seagen's top-line revenue, earnings per share and valuation.

Seagen has higher revenue and earnings than Moderna. Seagen is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Summary

Seagen beats Moderna on 13 of the 15 factors compared between the two stocks.

Moderna (NASDAQ:MRNA) and Bio-Techne (NASDAQ:TECH) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, dividends and profitability.

Analyst Ratings

This is a breakdown of recent recommendations for Moderna and Bio-Techne, as reported by MarketBeat.

Moderna presently has a consensus price target of $149.6471, suggesting a potential upside of 7.35%. Bio-Techne has a consensus price target of $367.50, suggesting a potential downside of 8.82%. Given Moderna's higher possible upside, equities analysts plainly believe Moderna is more favorable than Bio-Techne.

Risk & Volatility

Moderna has a beta of 1.73, indicating that its share price is 73% more volatile than the S&P 500. Comparatively, Bio-Techne has a beta of 1.13, indicating that its share price is 13% more volatile than the S&P 500.

Profitability

This table compares Moderna and Bio-Techne's net margins, return on equity and return on assets.

Institutional and Insider Ownership

51.2% of Moderna shares are held by institutional investors. Comparatively, 93.8% of Bio-Techne shares are held by institutional investors. 29.2% of Moderna shares are held by insiders. Comparatively, 3.8% of Bio-Techne shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Moderna and Bio-Techne's top-line revenue, earnings per share and valuation.

Bio-Techne has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Summary

Bio-Techne beats Moderna on 9 of the 14 factors compared between the two stocks.